Curious.
News today broke that Pfizer is no longer going to dedicate research money for obesity drugs. As we’ve all been told, obesity is an epidemic, so it would make sense for a drug company to focus their efforts on it. Right?
Not so fast. It turns out that most medicines involving obesity take one of three tacts:
Speeding up metabolism … think amphetamines.
Blocking absorption of calories … think Ali.
Appetite supression … think anti-depressants.
None have been successful to date.
In fact, Pfizer says :
Third, the ISP decisions were based on market opportunities and the potential for Pfizer to gain a leading position. They do not attempt to value the performance of any area or group.
Fascinating. It appears Pfizer understands that you cannot beat exercise and diet in terms of beating obesity.